ReviewCureus2026
Emerging Clinical Complications of Alpha-Gal Syndrome: A Scoping Review.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alpha-gal syndrome (AGS) is characterized by an IgE-mediated immune response against galactose-α-1,3-galactose (α-gal). In the United States, the principal vector is the lone star tick, whose range has expanded nationwide. A lone star tick bite delivers α-gal into human skin via its saliva, triggering an IgE response in susceptible individuals. Vomiting, urticaria, and anaphylaxis may occur immediately or hours after exposure. However, perioperative ingredients, such as gelatin, monoclonal antibodies, stearic acid, and other mammalian-derived products, have triggered anaphylactic shock in patients with AGS. These nuances complicate AGS management as many cases go unrecognized. This review aims to look beyond traditional food-related reactions, characterize the range of presentations, and improve management of this increasingly recognized condition. The inclusion criteria required original research in English peer-reviewed journals between January 1, 2000, and March 22, 2026. Eligible studies included quantitative, qualitative, and mixed-method designs examining AGS acquisition. Relevant tick studies were included. Systematic reviews, scoping reviews, meta-analyses, case reports, series, and studies involving pregnant individuals or children, lacking full-text, duplicate publications, or overlapping datasets were excluded. Authors screened publications using Rayyan (Rayyan Systems Inc., Cambridge, USA). Discrepancies were resolved through discussion. Of the 729 records identified, 14 studies met the inclusion criteria. Understanding the diverse spectrum of allergic manifestations of this condition is vital. This review consolidates findings on AGS-related complications, including immediate and delayed anaphylaxis, hypersensitivity reactions to mammalian-derived medical products, and blood transfusions. However, the available evidence is primarily derived from observational studies conducted in the United States, which may limit the generalizability of current findings. By highlighting the broader implications of AGS, this review underscores awareness in acute and perioperative settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.